Market Uptake Of New Incontinence Agents Impeded By Efficacy Perceptions, Novartis Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Public may view new overactive bladder treatments, such as Novartis' Enablex, as lacking efficacy advantages, according to the company.